COMPAMIR
High-Purity Fact Pipeline
© 2026 COMPAMIR | Verified Intelligence
High-Purity Fact Pipeline
The George Institute for Global Health
Global
June 8, 2026
"Large international studies show finerenone benefits non-diabetic chronic kidney disease (CKD) patients. The drug slows kidney function decline and reduces cardiovascular risks. Findings were published simultaneously in The Lancet, NEJM, and JAMA."
Author: Fiona Chin and Duncan Capicchiano
This book provides a comprehensive overview of the physiological mechanisms of chronic kidney disease and the lifestyle interventions necessary to manage it, offering a broader context for the pharmacological breakthroughs like Finerenone.